Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Ratio: 2021-2025

Historic Equity Ratio for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to 0.75.

  • Kiniksa Pharmaceuticals International's Equity Ratio fell 4.50% to 0.75 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75, marking a year-over-year decrease of 4.50%. This contributed to the annual value of 0.76 for FY2024, which is 9.42% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Equity Ratio stood at 0.75 for Q3 2025, which was up 0.39% from 0.75 recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Equity Ratio high stood at 0.88 for Q1 2023, and its period low was 0.72 during Q1 2022.
  • Moreover, its 3-year median value for Equity Ratio was 0.80 (2024), whereas its average is 0.80.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Equity Ratio fell by 17.26% in 2022 and then climbed by 22.38% in 2023.
  • Kiniksa Pharmaceuticals International's Equity Ratio (Quarterly) stood at 0.79 in 2021, then climbed by 8.43% to 0.86 in 2022, then decreased by 3.25% to 0.83 in 2023, then declined by 9.42% to 0.76 in 2024, then dropped by 4.50% to 0.75 in 2025.
  • Its last three reported values are 0.75 in Q3 2025, 0.75 for Q2 2025, and 0.76 during Q1 2025.